BIOTECHNOLOGY

FDI In Biotechnology Sectors

The biotechnology sector in the country has played a significant role in enhancing India’s global profile. India stands among the top 12 biotech destinations in the world and ranks third in the Asia Pacific, with approximately 3% share in the global biotechnology industry. The Biotechnology industry in India, comprising about 800 companies, assumes a critical role in the Indian economy. Biopharma is the largest sector contributing about 62 per cent of the total revenue followed by bio-services (18 per cent), bio-agri (15 per cent), bio-industry (4 per cent), and bio-informatics contributing (1 per cent).

By 2020, bio-incubation space of 175,000 sq. ft. has been planned with the target to support 50 world class bio-incubators. By 2025, Indian Biotechnology industry is expected to reach $100 bn.

100% FDI for biotechnology sector is allowed under the automatic route for green-field pharma.

100% FDI in biotechnology is allowed under the government route for brownfield pharma in up to 74% FDI is under automatic route and beyond 74% is under the government approval route.

Up to 100% FDI in biotechnology in India is allowed under the automatic route for the manufacturing of medical devices.

1

World’s largest producer of recombinant Hepatitis B vaccine
2

World’s largest 2-wheeler and 3-wheeler manufacturer
3

World’s 3rd largest heavy truck manufacturer and 4th largest car manufacturer

The sector is divided into five major segments- Bio-pharma, Bio-services, Bio-agri, Bio-industrial, and Bio-informatics

The biopharmaceutical sector accounts for the largest share of the biotech industry with a share of 64% of total revenues, followed by bio-services with 18% market share

India is becoming a leading destination for clinical trials, contract research, and manufacturing activities, which is further fuelling the growth of the bio-services sector

Bio-agri segments accounted for 14% of the biotech industry in 2015-16, while the remaining market is catered by bio-industrial (3%) and bio-informatics (1%)

India's Serum Institute is the largest Bio-pharma company in the country and accounts for approximately 22% of the biopharma market

30 bio-incubators and biotech parks have been supported and established during April 2014-September 2016

Growing population
India to become the world’s most populous country by 2030
Rising demand for treatments
Increased insurance penetration and a growing burden of disease
Medical infrastructure facilities
$ 200 Bn expenditure planned on medical infrastructure over the next decade
Strong skilled manpower pool
‘National Biopharma Mission’, an Industry-Academia mission to skill the workforce
Cost competitive manufacturing
Development of life-science clusters builds collaborations between research institutes and the private sector

Jul 2016: Helix investment Holdings Pte Ltd., Singapore invested $12 mn in Concord Biotech Ltd
Aug 2015: Tano India Pvt., Mauritius invested $7.4 mn in Windlas Biotech Ltd.